de novo protein / mAB design

Accelerate Discovery With ML/AI-Driven, Structure-First Antibody Engineering

Kemp Protein’s De Novo Antibody Design Services combine advanced computational protein engineering, ML/AI-guided sequence generation, and industry-leading analytical expertise to rapidly create novel antibody candidates with optimal affinity, stability, and manufacturability.

Whether you require a new lead, humanization-free novelty, or custom multi-specific antibody formats, we deliver FTO-friendly, rationally engineered candidates ready for expression and validation.

Service Overview

ML/AI-Driven Antibody Generation

Using next-generation machine learning models, we design novel, non-redundant antibody sequences tailored to your target epitope.
Capabilities include:

• Target-specific CDR design

• Germline selection and constraint-based engineering

• Multi-objective optimization for affinity, developability, and low immunogenicity

• Rapid exploration of thousands of sequence candidates

Structural Modeling & In Silico Validation

We integrate physics-based and deep-learning approaches to predict and optimize binding and stability:

• High-resolution structural modeling (AlphaFold-class tools)

• Antigen–antibody docking and scoring

• In silico affinity maturation

• Aggregation, PTM, and liability screening

• Fc and format modeling (IgG, Fab, scFv, VHH, bispecifics)

Prototype Expression & Purification

(Available as a standalone or integrated workflow)

• CHO, HEK293, or Pichia pastoris expression

• Affinity and tag-based purification

• Analytical development and QC

  • SEC-HPLC

  • Binding analytics (SPR/BLI/ELISA)

  • Antibody isotyping, conjugation, or amplification as needed

Functional Assay Support

• Antigen binding & competition assays

• Cell-based potency and mechanism-of-action assays

• Stability and developability testing

Formats We Support

We design and deliver a wide range of antibody modalities:

• Monoclonal antibodies (full-length IgGs)

• Fab, scFv, and VHH nanobodies

• Bispecific & multi-specific antibodies

• Antigen-binding fragments (Fab, F(ab’)₂)

• Anti-idiotype antibodies

• ADCs (antibody–drug conjugate-compatible scaffolds)

Deliverables

Every project includes a comprehensive engineering package:

• AI-designed antibody sequences (10–200+ variants)

• 3D models and docking files

• Annotated developability and liability reports

• Ranked shortlist of lead candidates

• Optional recombinant production and analytical validation

• Assay-ready purified antibody material (optional)

Applications

Our de novo design platform is ideal for:

• Novel or challenging targets lacking existing antibodies

• Projects requiring IP-unique and FTO-supportive sequences

• Bispecific and non-canonical antibody engineering

• Rapid early discovery or expansion of existing antibody pipelines

• ADC precursor design with defined conjugation sites

Why Partner With Us?

• Fully integrated AI + Wet Lab workflow
  From design to expression, analytics, and assay verification—under one roof.

• High-throughput in silico screening
  Evaluate thousands of variants before a single protein is produced.

• Quality-first development (Kemp Proteins–style rigor)
  Robust analytical and purification methods ensure stable, well-characterized prototypes.

• Modern AI-native engineering (ProtIQ.ai–style innovation)
  Advanced neural models trained on massive protein–antigen datasets.

• Flexible project models
  Design-only or full expression & validation packages.

Typical Project Timeline

• 2–4 weeks: Target assessment, ML/AI design, in silico scoring

• 3–6 weeks: Recombinant expression, purification & analytics

• 6–10 weeks: Full validation package with functional assays

(Timelines vary by format, complexity, and expression system.)

Get Started

Whether you need a fresh lead, a full antibody engineering campaign, or AI-driven sequence optimization, our team delivers rapid, reliable, and manufacturable candidates tailored to your therapeutic goals.